PRECIGEN Investors

Events & Presentations

Events & Presentations

Upcoming Events

More events are coming soon.

Past Events

Nov 15, 2023 at 10:55 AM - 11:25 AM EST
Helen Sabzevari, PhD, President and CEO, Precigen, presented a company overview at the Stifel 2023 Healthcare Conference on November 14-15, 2023 in New York.
New York, NY
Read More
Oct 26, 2023 at 2:00 PM EDT
Helen Sabzevari, PhD, President and CEO, Precigen, participated in an Acute Myeloid Leukemia (AML) panel discussion on Thursday, October 26.
Read More
Oct 24, 2023 at 5:00 PM - 7:00 PM CEST
Dr. Scott M. Norberg, Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, presented an abstract titled, "Significant clinical benefit and enhanced T-cell responses with repeated administration of PRGN-2012, a novel gorilla adenoviral vector based immunotherapy, in adult patients with severe Recurrent Respiratory Papillomatosis.
Brussels, Belgium
Read More
Oct 11, 2023 at 3:30 PM PDT
Helen Sabzevari, PhD, President and CEO, Precigen, provided a company presentation on Wednesday, October 11 at 3:30 PM PT at the Cell & Gene Meeting on the Mesa conference taking place from October 10 to 12 in Carlsbad, California.
Carlsbad, CA
Read More
Jun 02 - Jun 06, 2023
  • Abstract #2628: Phase I evaluation of PRGN-2009 alone and in combination with bintrafusp alfa in patients (pts) with recurrent/metastatic (R/M) HPV-associated cancers (HPV-C). Session Title: Developmental Therapeutics—Immunotherapy. Session Date and Time: June 3, 2023, 8:00 AM-11:00 AM CT.
  • Abstract #5590: Phase 1/1b study of PRGN-3005 autologous UltraCAR-T cells manufactured overnight for infusion next day to advanced stage platinum resistant ovarian cancer patients. Session Title: Gynecologic Cancer. Session Date and Time: June 5, 2023, 1:15 PM-4:15 PM CT.
Read More
Apr 17, 2023 at 9:00 AM - 12:30 PM EDT

An abstract titled, "Next generation UltraCAR-T® cells with intrinsic checkpoint inhibition and overnight manufacturing overcome suppressive tumor microenvironment leading to sustained antitumor activity," was presented as a poster presentation.

Read More
Apr 04, 2023 at 8:30 AM EDT
Precigen hosted a conference call to provide business and clinical updates for recent announcements.
Read More
Jan 24, 2023 at 4:30 PM EST
Precigen's virtual R&D day event showcased complete clinical trial safety and efficacy data from the Phase 1 dose escalation and expansion cohorts for the PRGN-2012 AdenoVerseTM immunotherapy in recurrent respiratory papillomatosis.
Read More
Dec 12, 2022 at 6:00 PM - 8:00 PM CST
An abstract (Abstract# 4633) titled, "Phase 1/1b Safety Study of PRGN-3006 UltraCAR-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes," was presented as a poster presentation.
Read More
Nov 09, 2022 at 4:30 PM EST
Precigen quarterly financial results and general business update. The conference call may be accessed by dialing 1-888-317-6003 (Domestic US), 1-866-284-3684 (Canada) or 1-412-317-6061 (International) and providing the participant access code 3010378. Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call.
Read More